This bill proposes to classify xylazine as a Schedule III controlled dangerous substance (CDS) in New Jersey, with the exception of its use in veterinary medicine. The amendment to Section 7 of P.L.1970, c.226 includes new legal language that specifies xylazine and its various forms as substances that fall under this classification, thereby subjecting them to standard criminal penalties associated with illegal activities such as manufacturing, distribution, and possession. The bill outlines that violations related to xylazine could result in a third-degree crime, punishable by three to five years of imprisonment and fines up to $25,000 for manufacturing and distribution, or up to $35,000 for possession and use.

The rationale behind this legislation stems from the increasing presence of xylazine in illegal street drugs, particularly opioids, where it is used to enhance the euphoric effects. Despite its veterinary applications, xylazine poses significant health risks, including severe withdrawal symptoms and the potential for overdose, especially since it does not respond to opioid antidotes like naloxone. The sponsors of the bill believe that regulating xylazine as a Schedule III CDS will help mitigate the risks associated with its misuse and ultimately protect public health in New Jersey.

Statutes affected:
Introduced: 24:21-7